The company launched Vigabatrin powder in 500 mg per packet, a therapeutic equivalent generic version of Sabril (vigabatrin) powder, approved by the US Food and Drug Administration (USFDA).
The Dr Reddy’s Laboratories’ stock gained more than a percent intraday on August 20 after the company launched Vigabatrin powder (oral solution).
The company launched Vigabatrin powder in 500 mg per packet, a therapeutic equivalent generic version of Sabril (vigabatrin) powder, approved by the US Food and Drug Administration (USFDA).
At 11:01 hours, the stock was quoting Rs 2,539.60, up Rs 29.10, or 1.16 percent on the BSE.
- Advertisement -DISCLAIMER
We have taken all measures to ensure that the information provided in this article and on our social media platform is credible, verified and sourced from other Big media Houses. For any feedback or complaint, reach out to us at businessleaguein@gmail.com
We have taken all measures to ensure that the information provided in this article and on our social media platform is credible, verified and sourced from other Big media Houses. For any feedback or complaint, reach out to us at businessleaguein@gmail.com
